Larvol Delta - First-patient-dosed-in-Clarity39s-registrational-Phase-III-prostate-cancer-trial-with-Cu64-SARbisPSMA

64/67Cu SAR-bisPSMA theranostic - Clarity Pharma

https://www.prnewswire.com/news-releases/first-patient-dosed-in-claritys-registrational-phase-iii-prostate-cancer-trial-with-cu-64-sar-bispsma-302021421.html

Dec 22, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next